Eleven’s Celniker Talks Leadership, Public Markets, and Phase III Dry Eye Trials - a podcast by OIS Podcast

from 2015-01-06T00:00

:: ::

Eleven Biotherapeutics capitalized on exciting technology and promising clinical results for its lead Dry Eye product to stage a successful IPO in 2014. Abbie C. Celniker, PhD, President and CEO, talks frankly about her leadership style, dealing with public investors, and how she’s man-aging high expectations for lead product EBI-005.